EP Patent

EP3398939A1 — Acrylanilide derivative, preparation method therefor, and applications thereof in pharmacy

Assigned to Ancureall Pharmaceutical Shanghai Co Ltd · Expires 2018-11-07 · 8y expired

What this patent protects

Disclosed in the present invention are an acrylanilide compound represented by general formula (I) and a pharmaceutically acceptable salt thereof. The acrylanilide compound and the pharmaceutically acceptable salt thereof are used for treating clinical diseases by mainly acting o…

USPTO Abstract

Disclosed in the present invention are an acrylanilide compound represented by general formula (I) and a pharmaceutically acceptable salt thereof. The acrylanilide compound and the pharmaceutically acceptable salt thereof are used for treating clinical diseases by mainly acting on EGFR family casein kinases.

Drugs covered by this patent

Patent Metadata

Patent number
EP3398939A1
Jurisdiction
EP
Classification
Expires
2018-11-07
Drug substance claim
No
Drug product claim
No
Assignee
Ancureall Pharmaceutical Shanghai Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.